Receive our newsletter – data, insights and analysis delivered to you
  1. Uncategorised
March 1, 2021

Coronavirus company news summary – MatMaCorp’s Covid-19 2SF RNA test effective in detecting variants – Therma Bright signs agreement for Covid-19 saliva-based antigen test

By Chloe Kent

MatMaCorp has announced efficacy data of its Covid-19 2SF RNA test when detecting SARS-CoV-2 variants. Preliminary evaluation of the data indicates that the test is capable of detecting more than 99.5% of the 3,801 coronavirus variants reported across the world till date.

Roche has been granted special approval by the German Federal Institute for Drugs and Medical Devices (BfArM) for its SARS-CoV-2 rapid antigen test. The test is expected to be widely available in Germany and enables at-home self-testing by patients with the help of a simple nasal swab.

Therma Bright has entered into an agreement with a Covid-19 testing site in the Greater Toronto Area to conduct a clinical trial of its AcuVid rapid antigen test, a saliva-based Covid-19 test. The testing site is expected to have one of the highest positivity rates in Ontario.

Related Companies

Content from our partners
Precision wire: The future of bespoke medical treatment
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
“This technique means everything to us”: How CGM devices empower users 
Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU